{
    "organizations": [],
    "uuid": "8a3c89773027740bf9804b506102011f72044ffe",
    "author": "",
    "url": "https://www.reuters.com/article/brief-valeant-reports-q1-loss-per-share/brief-valeant-reports-q1-loss-per-share-7-68-idUSASC0A0E8",
    "ord_in_thread": 0,
    "title": "BRIEF-Valeant Reports Q1 Loss Per Share $7.68",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8, 2018 / 11:20 AM / Updated 13 minutes ago BRIEF-Valeant Reports Q1 Loss Per Share $7.68 Reuters Staff\nMay 8 (Reuters) - Valeant Pharmaceuticals International Inc :\n* VALEANT ANNOUNCES FIRST-QUARTER 2018 RESULTS AND RAISES REVENUE AND ADJUSTED EBITDA (NON-GAAP) GUIDANCE\n* Q1 REVENUE $1.995 BILLION VERSUS I/B/E/S VIEW $1.94 BILLION * Q1 LOSS PER SHARE $7.68\n* Q1 EARNINGS PER SHARE VIEW $0.59 — THOMSON REUTERS I/B/E/S\n* VALEANT - COMPANY’S NAME WILL CHANGE TO BAUSCH HEALTH COMPANIES INC. IN JULY 2018\n* VALEANT SEES 2018 FULL-YEAR REVENUES IN RANGE OF $8.15 - $8.35 BILLION\n* VALEANT - REPAID APPROXIMATELY $280 MILLION OF DEBT WITH CASH ON HAND IN Q1 OF 2018\n* VALEANT SEES 2018 ADJUSTED EBITDA (NON-GAAP) IN RANGE OF $3.15 - $3.30 BILLION\n* QTRLY ADJUSTED NET INCOME ATTRIBUTABLE TO VALEANT PHARMACEUTICALS INTERNATIONAL INC $312 MILLION\n* VALEANT - GOODWILL IMPAIRMENT CHARGES OF $2.213 BILLION IN QUARTER RELATED TO SALIX AND ORTHO DERMATOLOGICS BUSINESSES Source text for Eikon: Further company coverage:",
    "published": "2018-05-08T14:16:00.000+03:00",
    "crawled": "2018-05-08T14:35:39.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "updated",
        "minute",
        "ago",
        "report",
        "q1",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "may",
        "reuters",
        "valeant",
        "pharmaceutical",
        "international",
        "inc",
        "valeant",
        "announces",
        "result",
        "raise",
        "revenue",
        "adjusted",
        "ebitda",
        "guidance",
        "q1",
        "revenue",
        "billion",
        "versus",
        "view",
        "billion",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "valeant",
        "company",
        "name",
        "change",
        "bausch",
        "health",
        "company",
        "july",
        "valeant",
        "see",
        "revenue",
        "range",
        "billion",
        "valeant",
        "repaid",
        "approximately",
        "million",
        "debt",
        "cash",
        "hand",
        "q1",
        "valeant",
        "see",
        "adjusted",
        "ebitda",
        "range",
        "billion",
        "qtrly",
        "adjusted",
        "net",
        "income",
        "attributable",
        "valeant",
        "pharmaceutical",
        "international",
        "inc",
        "million",
        "valeant",
        "goodwill",
        "impairment",
        "charge",
        "billion",
        "quarter",
        "related",
        "salix",
        "ortho",
        "dermatologics",
        "business",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}